{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:38:40Z","timestamp":1786984720967,"version":"build-2736575974"},"reference-count":66,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100006451","name":"Hospices Civils de Lyon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006451","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives de P\u00e9diatrie"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.arcped.2024.05.003","type":"journal-article","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T23:26:01Z","timestamp":1727393161000},"page":"410-418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Choice of compound, dosage, and management of side effects for long-term corticosteroid treatment in Duchenne muscular dystrophy: Guidelines from the Neuromuscular Commission of the French Society of Pediatric Neurology"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4486-2126","authenticated-orcid":false,"given":"St\u00e9phanie","family":"Fontaine Carbonnel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2324-1208","authenticated-orcid":false,"given":"Ivana","family":"Dabaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"de Montferrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0185-0659","authenticated-orcid":false,"given":"Pascal","family":"Rippert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Laugel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6543-8881","authenticated-orcid":false,"given":"Silvana","family":"De Lucia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Ravelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7090-3772","authenticated-orcid":false,"given":"Andreea","family":"Seferian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Ropars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Cances","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcped.2024.05.003_bib0001","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.arcped.2024.05.003_bib0002","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/mus.26736","article-title":"Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: a meta-analysis of disease progression rates in recent multicenter clinical trials","volume":"61","author":"McDonald","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.arcped.2024.05.003_bib0003","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1212\/WNL.0000000000002337","article-title":"Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"86","author":"Gloss","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.arcped.2024.05.003_bib0004","article-title":"Corticosteroids for the treatment of Duchenne muscular dystrophy","volume":"2016","author":"Matthews","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.arcped.2024.05.003_bib0005","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management","volume":"9","author":"Bushby","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.arcped.2024.05.003_bib0006","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003725.pub3","article-title":"Glucocorticoid corticosteroids for Duchenne muscular dystrophy","author":"Manzur","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.arcped.2024.05.003_bib0007","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3233\/JND-200609","article-title":"Adult north star network (ANSN): consensus guideline for the standard of care of adults with duchenne muscular dystrophy","volume":"8","author":"Quinlivan","year":"2021","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.arcped.2024.05.003_bib0008","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jpeds.2013.05.060","article-title":"Oral corticosteroids and onset of cardiomyopathy in duchenne muscular dystrophy","volume":"163","author":"Barber","year":"2013","journal-title":"J Pediatr"},{"key":"10.1016\/j.arcped.2024.05.003_bib0009","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.nmd.2015.07.009","article-title":"Benefits of glucocorticoids in non-ambulant boys\/men with Duchenne muscular dystrophy: a multicentric longitudinal study using the Performance of Upper Limb test","volume":"25","author":"Pane","year":"2015","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.arcped.2024.05.003_bib0010","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s13023-021-01862-w","article-title":"The clinical course of Duchenne muscular dystrophy in the corticosteroid treatment era: a systematic literature review","volume":"16","author":"Szabo","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.arcped.2024.05.003_bib0011","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/JND-170280","article-title":"Clinical Outcomes in Duchenne muscular dystrophy: a study of 5345 patients from the TREAT-NMD DMD global database","volume":"4","author":"Koeks","year":"2017","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.arcped.2024.05.003_bib0012","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/mus.27682","article-title":"Prognostic factors, disease course, and treatment efficacy in Duchenne muscular dystrophy: a systematic review and meta-analysis","volume":"66","author":"Weber","year":"2022","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.arcped.2024.05.003_bib0013","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.nmd.2005.03.004","article-title":"MFM collaborative study group. A motor function measure for neuromuscular diseases. Construction and validation study","volume":"15","author":"B\u00e9rard","year":"2005","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.arcped.2024.05.003_bib0014","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/j.apmr.2013.04.001","article-title":"Motor function measure: validation of a short form for young children with neuromuscular diseases","volume":"94","author":"de Lattre","year":"2013","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.arcped.2024.05.003_bib0015","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/mus.21544","article-title":"The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy","volume":"41","author":"McDonald","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.arcped.2024.05.003_bib0016","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1212\/WNL.0000000000001950","article-title":"Prednisone\/prednisolone and deflazacort regimens in the CINRG Duchenne natural history study","volume":"85","author":"Bello","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.arcped.2024.05.003_bib0017","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/mus.26191","article-title":"Deflazacort versus prednisone\/prednisolone for maintaining motor function and delaying loss of ambulation: A post HOC analysis from the ACT DMD trial","volume":"58","author":"Shieh","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.arcped.2024.05.003_bib0018","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2217\/cer-2019-0170","article-title":"Real-world outcomes of long-term prednisone and deflazacort use in patients with Duchenne muscular dystrophy: experience at a single, large care center","volume":"9","author":"Marden","year":"2020","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.arcped.2024.05.003_bib0019","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1001\/jama.2022.4315","article-title":"Effect of different corticosteroid dosing regimens on clinical outcomes in boys with Duchenne muscular dystrophy: a randomized clinical trial","volume":"327","author":"Guglieri","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.arcped.2024.05.003_bib0020","article-title":"Corticosteroids for the treatment of Duchenne muscular dystrophy","volume":"2016","author":"Matthews","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.arcped.2024.05.003_bib0021","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1097\/WNR.0000000000000028","article-title":"A novel treatment regimen for Duchenne muscular dystrophy","volume":"24","author":"Li","year":"2013","journal-title":"NeuroReport"},{"key":"10.1016\/j.arcped.2024.05.003_bib0022","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/s00415-009-5012-y","article-title":"Prednisone 10 days on\/10 days off in patients with Duchenne muscular dystrophy","volume":"256","author":"Straathof","year":"2009","journal-title":"J Neurol"},{"key":"10.1016\/j.arcped.2024.05.003_bib0023","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1212\/WNL.0b013e318227b164","article-title":"Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy","volume":"77","author":"Escolar","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.arcped.2024.05.003_bib0024","article-title":"The PJ Nicholoff steroid protocol for Duchenne and Becker muscular dystrophy and adrenal suppression","volume":"9","author":"Kinnett","year":"2017","journal-title":"PLoS Curr"},{"key":"10.1016\/j.arcped.2024.05.003_bib0025","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1542\/peds.2018-0333E","article-title":"Bone health and osteoporosis management of the patient with Duchenne muscular dystrophy","volume":"142","author":"Ward","year":"2018","journal-title":"Pediatrics"},{"key":"10.1016\/j.arcped.2024.05.003_bib0026","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.arcped.2024.05.003_bib0027","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.arcped.2020.07.008","article-title":"Guidelines for the management of children at risk of secondary bone fragility: Expert opinion of a French working group","volume":"27","author":"Edouard","year":"2020","journal-title":"Arch P\u00e9diatr"},{"key":"10.1016\/j.arcped.2024.05.003_bib0028","series-title":"Dietary reference intakes: the essential guide to nutrient requirements","author":"Meyers","year":"2006"},{"key":"10.1016\/j.arcped.2024.05.003_bib0029","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique","volume":"8","author":"Genant","year":"1993","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.arcped.2024.05.003_bib0030","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.nmd.2011.02.006","article-title":"Endocrine aspects of Duchenne muscular dystrophy","volume":"21","author":"Bianchi","year":"2011","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.arcped.2024.05.003_bib0031","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13023-021-02158-9","article-title":"Growth pattern trajectories in boys with Duchenne muscular dystrophy","volume":"17","author":"Stimpson","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.arcped.2024.05.003_bib0032","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jaapos.2018.01.017","article-title":"Cataract development associated with long-term glucocorticoid therapy in Duchenne muscular dystrophy patients","volume":"22","author":"Rice","year":"2018","journal-title":"J Am Assoc Pediatr Ophthalmol Strabismus"},{"key":"10.1016\/j.arcped.2024.05.003_bib0033","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jaapos.2018.07.347","article-title":"Cataract development associated with long-term glucocorticoid therapy in Duchenne muscular dystrophy patients","volume":"22","author":"Brignol","year":"2018","journal-title":"J AAPOS"},{"key":"10.1016\/j.arcped.2024.05.003_bib0034","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/1097-4598(200009)23:9<1344::AID-MUS4>3.0.CO;2-F","article-title":"A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy","volume":"23","author":"Bonifati","year":"2000","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.arcped.2024.05.003_bib0035","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1001\/archneur.62.1.128","article-title":"Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial","volume":"62","author":"Beenakker","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.arcped.2024.05.003_bib0036","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/s00246-005-0909-4","article-title":"Steroid therapy and cardiac function in Duchenne muscular dystrophy","volume":"26","author":"Markham","year":"2005","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.arcped.2024.05.003_bib0037","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/mus.24665","article-title":"Daily prednisone treatment in Duchenne muscular dystrophy in southwest China","volume":"52","author":"Hu","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.arcped.2024.05.003_bib0038","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1136\/jnnp-2012-303902","article-title":"Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy","volume":"84","author":"Ricotti","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.arcped.2024.05.003_bib0039","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.nmd.2015.01.005","article-title":"Renal function in children and adolescents with Duchenne muscular dystrophy","volume":"25","author":"Braat","year":"2015","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.arcped.2024.05.003_bib0040","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1161\/HYPERTENSIONAHA.108.190329","volume":"52","author":"Urbina","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.arcped.2024.05.003_bib0041","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1161\/HYP.0000000000000007","article-title":"Update: ambulatory blood pressure monitoring in children and adolescents: a scientific statement from the American Heart Association","volume":"63","author":"Flynn","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.arcped.2024.05.003_bib0042","first-page":"551","article-title":"Behavior of blood pressure variables in children and adolescents with Duchenne muscular dystrophy","volume":"110","author":"Marui","year":"2018","journal-title":"Arq Bras Cardiol"},{"key":"10.1016\/j.arcped.2024.05.003_bib0043","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s00246-017-1657-y","article-title":"Central arterial function measured by non-invasive pulse wave analysis is abnormal in patients with Duchenne muscular dystrophy","volume":"38","author":"Ryan","year":"2017","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.arcped.2024.05.003_bib0044","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1007\/s00467-020-04587-3","article-title":"Kidney involvement and associated risk factors in children with Duchenne muscular dystrophy","volume":"35","author":"Kutluk","year":"2020","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.arcped.2024.05.003_bib0045","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrcardio.2013.213","article-title":"Treatment of dystrophin cardiomyopathies","volume":"11","author":"Finsterer","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.arcped.2024.05.003_bib0046","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s00246-015-1191-8","article-title":"Under-recognition of low blood pressure readings in patients with Duchenne muscular dystrophy","volume":"36","author":"Masood","year":"2015","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.arcped.2024.05.003_bib0047","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/JND-180340","article-title":"Increased blood pressure and body mass index as potential modifiable factors in the progression of myocardial dysfunction in Duchenne muscular dystrophy","volume":"6","author":"van de Velde","year":"2019","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.arcped.2024.05.003_bib0048","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13023-019-1066-9","article-title":"Effect and safety of treatment with ACE-inhibitor Enalapril and \u03b2-blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy - a randomized, double-blind, placebo-controlled trial","volume":"14","author":"Dittrich","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.arcped.2024.05.003_bib0049","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ejpn.2017.02.007","article-title":"Assessing mental health in boys with Duchenne muscular dystrophy: Emotional, behavioural and neurodevelopmental profile in an Italian clinical sample","volume":"21","author":"Colombo","year":"2017","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.arcped.2024.05.003_bib0050","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.nmd.2016.08.003","article-title":"Diagnosis and treatment of obsessive compulsive behavior in a boy with Duchenne muscular dystrophy and autism spectrum disorder: A case report","volume":"26","author":"Hendriksen","year":"2016","journal-title":"Neuromuscul Disord NMD"},{"key":"10.1016\/j.arcped.2024.05.003_bib0051","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/mus.26803","article-title":"Neurodevelopmental, behavioral, and emotional symptoms common in Duchenne muscular dystrophy","volume":"61","author":"Darmahkasih","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.arcped.2024.05.003_bib0052","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1469-8749.1998.tb15351.x","article-title":"Reading ability and processing in Duchenne muscular dystrophy and spinal muscular atrophy","volume":"40","author":"Billard","year":"1998","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.arcped.2024.05.003_bib0053","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.neurol.2013.04.004","article-title":"[Phenotypic heterogeneity and phenotype-genotype correlations in dystrophinopathies: Contribution of genetic and clinical databases]","volume":"169","author":"Humbertclaude","year":"2013","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.arcped.2024.05.003_bib0054","article-title":"Working memory alterations plays an essential role in developing global neuropsychological impairment in Duchenne muscular dystrophy","volume":"11","author":"Tyagi","year":"2020","journal-title":"Front Psychol"},{"key":"10.1016\/j.arcped.2024.05.003_bib0055","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejpn.2018.09.005","article-title":"Methylphenidate use in males with Duchenne muscular dystrophy and a comorbid attention-deficit hyperactivity disorder","volume":"23","author":"Lionarons","year":"2019","journal-title":"Eur J Paediatr Neurol EJPN"},{"key":"10.1016\/j.arcped.2024.05.003_bib0056","unstructured":"Fili\u00e8re de sant\u00e9 Maladies rares-Maladies neuromusculaires; Soci\u00e9t\u00e9 Fran\u00e7aise de Neurop\u00e9diatrie. [Internet] Protocole National de Diagnostic et de Soins (PNDS) Dystrophie musculaire de Duchenne; 2019. https:\/\/www.has-sante.fr\/jcms\/p_3121365\/fr\/dystrophie-musculaire-de-duchenne."},{"key":"10.1016\/j.arcped.2024.05.003_bib0057","unstructured":"HCSP. [Internet] Vaccination des personnes immunod\u00e9prim\u00e9es ou aspl\u00e9niques; 2012. https:\/\/www.hcsp.fr\/explore.cgi\/avisrapportsdomaine?clefr=504."},{"key":"10.1016\/j.arcped.2024.05.003_bib0058","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.nmd.2018.05.004","article-title":"Nutrition in Duchenne muscular dystrophy 16\u201318 March 2018, Zaandam, the Netherlands","volume":"28","author":"Verhaart","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.arcped.2024.05.003_bib0059","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.nut.2015.09.004","article-title":"Impact of corticotherapy, nutrition, and sleep disorder on quality of life of patients with Duchenne muscular dystrophy","volume":"32","author":"Jeronimo","year":"2016","journal-title":"Nutrition"},{"key":"10.1016\/j.arcped.2024.05.003_bib0060","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/0883073814530502","article-title":"Strong correlation between the 6-minute walk test and accelerometry functional outcomes in boys with Duchenne muscular dystrophy","volume":"30","author":"Davidson","year":"2015","journal-title":"J Child Neurol"},{"key":"10.1016\/j.arcped.2024.05.003_bib0061","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.dsx.2017.08.006","article-title":"Energy expenditure, body composition, and prevalence of metabolic disorders in patients with Duchenne muscular dystrophy","volume":"12","author":"Saure","year":"2018","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"key":"10.1016\/j.arcped.2024.05.003_bib0062","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3390\/nu9060594","article-title":"Nutritional challenges in Duchenne muscular dystrophy","volume":"9","author":"Salera","year":"2017","journal-title":"Nutrients"},{"key":"10.1016\/j.arcped.2024.05.003_bib0063","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.3109\/09638288.2015.1111434","article-title":"Dysphagia in Duchenne muscular dystrophy: practical recommendations to guide management","volume":"38","author":"Toussaint","year":"2016","journal-title":"Disabil Rehabil"},{"key":"10.1016\/j.arcped.2024.05.003_bib0064","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/0003-9993(94)90001-9","article-title":"Swallowing problems in neuromuscular disorders","volume":"75","author":"Willig","year":"1994","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.arcped.2024.05.003_bib0065","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jpeds.2015.12.046","article-title":"Constipation in Duchenne muscular dystrophy: prevalence, diagnosis, and treatment","volume":"171","author":"Kraus","year":"2016","journal-title":"J Pediatr"},{"key":"10.1016\/j.arcped.2024.05.003_bib0066","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejpn.2021.11.004","article-title":"Implementation of motor function measure score percentile curves - predicting motor function loss in Duchenne muscular dystrophy","volume":"36","author":"Hafner","year":"2022","journal-title":"Eur J Paediatr Neurol"}],"container-title":["Archives de P\u00e9diatrie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929693X24001350?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929693X24001350?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T01:27:21Z","timestamp":1729560441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929693X24001350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":66,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0929693X24001350"],"URL":"https:\/\/doi.org\/10.1016\/j.arcped.2024.05.003","relation":{},"ISSN":["0929-693X"],"issn-type":[{"value":"0929-693X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Choice of compound, dosage, and management of side effects for long-term corticosteroid treatment in Duchenne muscular dystrophy: Guidelines from the Neuromuscular Commission of the French Society of Pediatric Neurology","name":"articletitle","label":"Article Title"},{"value":"Archives de P\u00e9diatrie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcped.2024.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Soci\u00e9t\u00e9 fran\u00e7aise de p\u00e9diatrie. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}